WO2002005747A3 - The process of manufacturing pharmaceutical grade tannates - Google Patents
The process of manufacturing pharmaceutical grade tannates Download PDFInfo
- Publication number
- WO2002005747A3 WO2002005747A3 PCT/IB2001/001254 IB0101254W WO0205747A3 WO 2002005747 A3 WO2002005747 A3 WO 2002005747A3 IB 0101254 W IB0101254 W IB 0101254W WO 0205747 A3 WO0205747 A3 WO 0205747A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tannates
- tannic acid
- isopropanol
- tannate
- antihistamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Antihistamines are available in the form of fee bases as well as salt i.e. hydrochloride, maleate, tannate, etc. Frequently, it is necessary to utilise antihistamines in the form of tannate salt because such salts are generally quite stable and may be administered in such from without untoward side effects. Tannic acid, also known as tannin, is a well know naturally occurring substance. Tannic acid, which is available commercially, usually contain about 5 % of water, has a molecular weight of about 1700 and is typically produced from Turkish or Chinese nutgall. Antihistamine tannates, presently manufactured commercially, are relatively impure. Such tannates are prepared by the reaction of antihistamine free base with tannic acid and using a volatile solvent, isopropanol (IPA). The yield is only fair (around 70 %) and decomposition products e.g. 2-5 % along with significant amount of volatile solvent, isopropanol (6-10 %) remains with the product, which cannot be removed. According to present invention, the tannates are made by dissolving tannic acid and amine in different compatible solvents. The solvents can be halogenated alkanes or alkanoic esters. The examples of halogenated alkane is chloroform, and that of alkanoic ester is ethyl acetate. This avoids the use of isopropanol. This method gives tannates which are lighter in colour. Ephedrine and Pseudoephredine tannates are prepared by using ethyl acetate as a medium for reactions to get pharmaceutical grade tannate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN661/MUM/2000 | 2000-07-14 | ||
| IN661MU2000 | 2000-07-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002005747A2 WO2002005747A2 (en) | 2002-01-24 |
| WO2002005747A3 true WO2002005747A3 (en) | 2002-10-10 |
Family
ID=11097264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2001/001254 Ceased WO2002005747A2 (en) | 2000-07-14 | 2001-07-13 | The process of manufacturing pharmaceutical grade tannates |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2002005747A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL364087A1 (en) | 2001-02-21 | 2004-12-13 | Basf Aktiengesellschaft | Method for the production of d-pantothenic acid and/or salts thereof as adjunct for animal feedstuffs |
| US20030114535A1 (en) | 2001-12-14 | 2003-06-19 | Jame Fine Chemicals, Inc. | Dextrochlorpheniramine tannate |
| US6677381B1 (en) | 2001-12-14 | 2004-01-13 | Jame Fine Chemicals, Inc. | Guaifenesin tannate |
| US6670370B1 (en) | 2001-12-14 | 2003-12-30 | Jame Fine Chemicals, Inc. | Dextromethorphan tannate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282789A (en) * | 1963-05-17 | 1966-11-01 | Neisler Lab Inc | Stable liquid colloidal tannate compositions |
| US5599846A (en) * | 1996-06-28 | 1997-02-04 | Jame Fine Chemicals, Inc. | Phenylephrine tannate compositions |
| US5663415A (en) * | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
-
2001
- 2001-07-13 WO PCT/IB2001/001254 patent/WO2002005747A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282789A (en) * | 1963-05-17 | 1966-11-01 | Neisler Lab Inc | Stable liquid colloidal tannate compositions |
| US5599846A (en) * | 1996-06-28 | 1997-02-04 | Jame Fine Chemicals, Inc. | Phenylephrine tannate compositions |
| US5663415A (en) * | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002005747A2 (en) | 2002-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003086392A3 (en) | Process for preparing a finely self-emulsifiable pharmaceutical composition | |
| US4956391A (en) | Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease | |
| CA2170622A1 (en) | Oral Formulations of an Antifungal | |
| US10307485B2 (en) | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive | |
| WO2011018635A3 (en) | Photosensitizing compositions | |
| CA2356959A1 (en) | Water-insoluble drug delivery system | |
| JP2001527514A (en) | Modifiers for sympathomimetic amine salts | |
| JP2002541238A (en) | Esters of L-carnitine or alkanoyl L-carnitine useful as cationic lipids for intracellular delivery of pharmacologically active compounds | |
| JP2023106478A (en) | Long-Acting Injectable Formulations and Crystalline Forms of Buprenorphine Derivatives | |
| WO2002005747A3 (en) | The process of manufacturing pharmaceutical grade tannates | |
| CA2438854A1 (en) | Method of preparing non-hydrated fexofenadine hydrochloride and novel crystalline form obtainable by this method | |
| WO2002005746A3 (en) | The process of manufacturing pharmaceutical grade tannates | |
| AU2001239625A1 (en) | Method of preparing solid dispersions | |
| AU8238398A (en) | Tramadol, salts thereof and process for their preparation | |
| WO2002005745A3 (en) | The process of manufacturing pharmaceutical grade tannates | |
| MX2014012764A (en) | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimet hyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a gabapentinoid. | |
| US6096760A (en) | Solid α-phenyl-2-piperidine acetate free base, its preparation and use in medicine | |
| WO2004075900A2 (en) | Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent | |
| MXPA06002066A (en) | Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions. | |
| KR102004552B1 (en) | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate | |
| ATE277039T1 (en) | FARNESYL TRANSFERASE INHIBITORS THAT HAVE A PYRROLE STRUCTURE AND METHOD FOR THE PRODUCTION THEREOF | |
| KR101273840B1 (en) | Complex containing mequitazine, a cyclodextrin and an interaction agent | |
| US20020072602A1 (en) | Micronized mirtazapine | |
| KR100220878B1 (en) | Composition for treating cognitive disorders containing certain esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds | |
| US6790857B2 (en) | Benzoylecgonine compositions and methods for producing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA MX US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA MX US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| ENP | Entry into the national phase |
Ref document number: 20030935 Country of ref document: UZ Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Country of ref document: RU Kind code of ref document: A Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |